Q2 2025 · 13F-HR
Flagship Pioneering, LLCholdings as filed
Filed 2025-08-14 · accession 0000950123-25-008304
$268.5M
Reported value
4
Positions
2025-06-30
Period end
The Brief · Flagship Pioneering, LLC · Q2 2025
AI · grounded in 13F
Flagship Pioneering, LLC established a new position in Moderna Inc MRNA valued at $127.8M. The fund also initiated new stakes in Sana Biotechnology Inc SANA for $68.3M and Foghorn Therapeutics Inc FHTX for $59.6M. A final new position was added in Seres Therapeutics Inc MCRB totaling $12.8M. These four positions bring the fund's total AUM to $268.5M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 60770K107 | MRNA | Moderna Inc | $127.8M | 47.6% | 4,632,149 | Common | SHARED |
| 799566104 | SANA | Sana Biotechnology Inc | $68.3M | 25.4% | 25,001,856 | Common | SHARED |
| 344174107 | FHTX | Foghorn Therapeutics Inc | $59.6M | 22.2% | 12,674,120 | Common | SHARED |
| 81750R201 | MCRB | Seres Therapeutics Inc | $12.8M | 4.78% | 1,155,850 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.